- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Solid Performers
U.S. Pharmaceuticals & Biotech Undervalued Solid Performers
UPDATED Oct 26, 2023
Companies meeting several financial criteria and filtered from the entire market.
7 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals | US$361.28 | -1.0% | 25.5% | US$93.7b | US$385.67 | PE27.7x | E10.4% | n/a | ||
| REGNRegeneron Pharmaceuticals | US$792.01 | -2.1% | 9.3% | US$84.5b | US$902.36 | PE19.5x | E6.0% | n/a | ||
| BMRNBioMarin Pharmaceutical | US$81.97 | -0.8% | -4.4% | US$15.4b | US$115.79 | PE154.3x | E40.3% | n/a | ||
| NBIXNeurocrine Biosciences | US$107.92 | -2.9% | -5.2% | US$10.6b | US$134.64 | PE59.7x | E33.8% | n/a | ||
| UTHRUnited Therapeutics | US$224.40 | -0.6% | -0.6% | US$10.5b | US$280.88 | PE12.1x | E12.1% | n/a | ||
| OLKOlink Holding | US$24.80 | 0.4% | 35.9% | US$3.1b | US$26.00 | PS21x | E107.4% | n/a | ||
| PRTAProthena | US$33.88 | -24.0% | -43.2% | US$2.1b | US$87.89 | PS31.5x | E6.6% | n/a |
Page 1 of 1